Pirelli H1 Revenue Hits €3.5 Billion Net Income Up 14 Percent High-Value Tire Sales Surge to 80 Percent
On July 31, Pirelli reported first-half 2025 results with revenue reaching €3.499 billion, reflecting a solid organic growth rate of 4.4%. Adjusted EBIT climbed to €558 million, up €19.2 million from the previous year, pushing the EBIT margin to 16.0% (vs. 15.6% last year). This improvement, driven by internal efficiencies, nearly offset headwinds from FX volatility, higher raw material costs, inflation, and new US tariffs effective May 3.
Net income soared 14.1% to €264 million, compared to €231 million a year earlier. Q2 alone saw revenue of €1.74 billion, with organic growth at 4.0% despite a slight 0.7% year-on-year decline in euro terms.
Pirelli’s high-value strategy continues to pay off—premium and performance tire sales now account for 80% of total revenue, up from 77% last year. The company credits its success to innovation and tailored product offerings, further reinforcing its leadership in the luxury and high-performance tire segments.
2026-10-04
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Is Evonik’s Massive Global Expansion of Hydroxyl-Terminated Polybutadiene (HTPB) a Technological Ambition — or a Geopolitical Gamble?
-
BASF Moves to Sell 4,400 Employee Homes—Union Fury Reveals the Survival Math of a Chemical Giant
-
The Most Striking Thing in BASF’s 2025 Results Isn’t Profit — It’s “Cutting Weight” and “Stopping the Bleeding” at the Same Time
-
BASF Battles Market Turmoil as Profits Slide
-
Beiersdorf Launches Eucerin Skincare Brand in Japan
-
From Desert Sands to Dining Tables: Arab Food & Beverage Sector Emerges as Investment Powerhouse
-
Yulong Petrochemical’s 100,000-ton MMA Project Comes Online Amid a “Deep V-Shaped Rebound” — Opportunity or Hidden Risk?
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value
-
Exit! Why Did Clariant Divest Its Venezuelan Business at a “Low Price”?
Recommend Reading
-
Huafon Chemical Plans RMB 6.85 Billion Acquisition to Expand Its TPU and PU Resin Portfolio
-
LANXESS Expands Rubber Additives Production at Qingdao Plant
-
UK AGC Plans to Close PFAS Plant as Pressure on Europe’s Fluorochemicals Sector Intensifies
-
BASF Plans IPO for Agricultural Solutions Business
-
Sinopec Completes CNAF Restructuring, Integrating the Entire Aviation Fuel Chain
-
Upward Momentum Fades, Formic Acid Prices Return to Stable Operation
-
This Weekend China's Hydrofluoric Acid Market Rises Slightly (7.6-7.10)
-
This Week's Epichlorohydrin Market Transaction Focus Shifted Upward and Stabilized (11.10-11.14)
-
This Week, the Transaction Focus of China's Propylene Oxide Market Rises (11.10-11.14)
-
Premium Global Chemical Sourcing Requests (10-14 Nov 2025)